Treatment of enterocutaneous fistulas with TPN and somatostatin, compared with patients who received TPN only

Eighteen patients with post-operative enterocutaneous fistulas were treated with total parenteral nutrition (TPN), skin care, infection control and intravenous somatostatin (SMS) 250 micrograms/h. This group was compared with 30 patients treated with standard medical treatment (total parenteral nutrition (TPN), skin care and infection control). In the SMS group the fistula output was reduced to 50% in three days and spontaneous closure was observed in 14 patients after a mean of 6.1 +/- 3.1 days of treatment with SMS, and in 18.2 +/- 6.3 days after the TPN administration. In the control group the fistula output was reduced by up to 50% after a week and spontaneous closure occurred in 20 patients in a mean of 27.4 +/- 8.7 days after the start of treatment. These results are statistically significant. There was one (5.5%) death in the SMS group compared with three (10%) deaths in the other, and glucose intolerance was observed in two (11%) patients in the SMS group. Somatostatin has been shown to be useful in the conservative treatment of enterocutaneous fistulas because of its ability to reduce output and accelerate closure.

[1]  M. Gil,et al.  Treatment of 27 Postoperative Enterocutaneous Fistulas with the Long Half‐life Somatostatin Analogue SMS 201–995 , 1989, Annals of surgery.

[2]  A. Sitges-Serra,et al.  BLIND EVALUATION OF THE EFFECT OF OCTREOTIDE (SMS 201-995), A SOMATOSTATIN ANALOGUE, ON SMALL-BOWEL FISTULA OUTPUT , 1987, The Lancet.

[3]  S. Mulvihill,et al.  The use of somatostatin and its analogs in the treatment of surgical disorders. , 1986, Surgery.

[4]  P. Marbach,et al.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. , 1982, Life sciences.

[5]  E. Jaurrieta,et al.  Management of postoperative enterocutaneous fistulas: The roles of parenteral nutrition and surgery , 1982, The British journal of surgery.

[6]  J. Bosch,et al.  Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: Comparison with vasopressin , 1981 .

[7]  A. M. Ebeid,et al.  Review of 404 Patients with Gastrointestinal Fistulas Impact of Parenteral Nutrition , 1979, Annals of surgery.

[8]  A. Schally,et al.  Effect of somatostatin on myoelectrical activity of small bowel. , 1978, The American journal of physiology.

[9]  O. Owen,et al.  Somatostatin suppresses secretin and pancreatic exocrine secretion , 1975, Science.

[10]  A. Schally,et al.  Somatostatin: abundance of immunoreactive hormone in rat stomach and pancreas. , 1975, Science.

[11]  J. Bosch,et al.  Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. , 1981, Gastroenterology.